Teva Pharmaceutical Industries ADR (TEVA)

$36.44 -1.18 (-3.14%)
Market Cap 43.84B
Revenue (ttm) 17.26B
Net Income (ttm) 1.41B
EPS (ttm) N/A
PE Ratio 17.39
Forward PE 19.40
Profit Margin 8.18%
Debt to Equity Ratio 2.14
Volume 3,140,900
Avg Vol 5,513,664
Day's Range N/A - N/A
Shares Out 1.17B
Stochastic %K 5%
Beta 0.86
Analysts Strong Sell
Price Target $41.60

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 914 8213
Address:
124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel
Joebeemer
Joebeemer Aug. 29 at 2:32 AM
$TEVA when you look at this stick price over a long period of time. Especially like the 5yr timeline, it's been steadily rising. Dips occur,but it comes back higher. May have to hold longer but this should keep climbing
0 · Reply
Terrordomo80
Terrordomo80 Aug. 28 at 9:24 PM
$TEVA but...but...52 week highs...
0 · Reply
SdotRayborn
SdotRayborn Aug. 28 at 5:42 PM
$TEVA no volume until the 18th when it’s directly listed on the NYSE I guess. Volume been so dead for months.
0 · Reply
Paulbpaulb
Paulbpaulb Aug. 28 at 4:24 PM
$BTAI maybe it’s a good time to buy a chunk of $TEVA ?
1 · Reply
Joebeemer
Joebeemer Aug. 28 at 3:54 PM
$TEVA this should come up substantially with the acquisition news of $BTAI Maybe Mondays runners
0 · Reply
flychicken1991
flychicken1991 Aug. 28 at 10:31 AM
$TEVA Mixed (76%): shares could rise if the acquired product adds credible revenue and earnings potential at a disciplined cost, but they could be pressured if the purchase price, financing burden, regulatory risk... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/323214d3cd0bed30/teva-teva-announces-proposed-acquisition-of-a-novel-neuroscience-product?utm_source=stocktwits&utm_medium=story_url
0 · Reply
G101SPM
G101SPM Aug. 28 at 10:21 AM
$TEVA $37.21 bid Holding long position at $5.77 Review entire column https://stocktwits.com/G101SPM/message/646531082 UPDATE:Teva Pharma to serve as stalking horse bidder for substantially all BioXcel Therapeutics (BTAI) assets note: Teva Pharmaceutical Industries subsidiary Teva Pharmaceuticals International entered into an asset sale agreement to acquire substantially all of BioXcel Therapeutics' assets, subject to a court-supervised Chapter 11 auction process. Teva will serve as the sole stalking horse bidder, establishing the baseline offer for a Section 363 auction that allows competing bids for some or all of BioXcel's assets. Assets covered by the agreement include IGALMI (dexmedetomidine) sublingual film and the pending sNDA for BXCL501 for potential at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel concurrently filed for Chapter 11 protection and secured a $19 mln DIP financing commitment; the BXCL501 sNDA has a November 14, 2026 PDUFA date.
0 · Reply
Hopewisper
Hopewisper Aug. 28 at 5:22 AM
$TEVA
0 · Reply
layahoo
layahoo Aug. 28 at 3:05 AM
$TEVA Where’s that low lying weakling??? lol
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Aug. 27 at 7:01 PM
$TEVA printed a new 52-week high today
0 · Reply
Latest News on TEVA
Teva unit bids to acquire neuroscience product from BioXcel Therapeutics

2026-08-28T10:26:39.000Z - 1 day ago

Teva unit bids to acquire neuroscience product from BioXcel Therapeutics

BTAI

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

Fri, 28 Aug 2026 06:17:00 -0400 - 1 day ago

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

BioXcel Therapeutics enters asset sale agreement with Teva

2026-08-28T10:05:11.000Z - 1 day ago

BioXcel Therapeutics enters asset sale agreement with Teva

BTAI

Aurinia settles patent litigation with Teva

2026-08-19T20:11:02.000Z - 9 days ago

Aurinia settles patent litigation with Teva

AUPH

Aurinia Settles Patent Litigation with Teva

Wed, 19 Aug 2026 16:05:00 -0400 - 9 days ago

Aurinia Settles Patent Litigation with Teva

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

2026-08-19T15:16:03.000Z - 9 days ago

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

Teva announces FDA acceptance of ecopipam NDA

2026-08-19T12:45:52.000Z - 9 days ago

Teva announces FDA acceptance of ecopipam NDA

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Wed, 19 Aug 2026 08:30:00 -0400 - 9 days ago

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Teva price target raised to $42 from $40 at Barclays

2026-08-17T10:59:59.000Z - 12 days ago

Teva price target raised to $42 from $40 at Barclays

Teva price target raised to $42 from $40 at Barclays

2026-08-17T10:19:43.000Z - 12 days ago

Teva price target raised to $42 from $40 at Barclays

Humana agrees not to reference Teva's Israel ties at US drug trial

Thu, 13 Aug 2026 10:16:17 -0400 - 15 days ago

Humana agrees not to reference Teva's Israel ties at US drug trial

TEVA Maintained by Barclays -- Price Target Raised to $42.00

2026-08-12T14:30:27.000Z - 16 days ago

TEVA Maintained by Barclays -- Price Target Raised to $42.00

Teva (TEVA) Q2 2026 Earnings Call Transcript

2026-08-07T23:42:43.000Z - 21 days ago

Teva (TEVA) Q2 2026 Earnings Call Transcript

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

2026-08-07T15:40:02.000Z - 21 days ago

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Teva seeks to keep Israel ties from jury, cites Gaza war

Thu, 06 Aug 2026 12:22:34 -0400 - 22 days ago

Teva seeks to keep Israel ties from jury, cites Gaza war

Why Teva Pharmaceutical Stock Surged This Week

Sun, 02 Aug 2026 12:44:19 -0400 - 26 days ago

Why Teva Pharmaceutical Stock Surged This Week

Teva Pharmaceutical Industries Q2 Earnings Call Highlights

Thu, 30 Jul 2026 08:04:18 -0400 - 4 weeks ago

Teva Pharmaceutical Industries Q2 Earnings Call Highlights

TEVA SWOT Analysis: Financial Struggles Amidst Strategic Shifts Revealed in 10-Q Filing

2026-07-30T05:05:15.000Z - 4 weeks ago

TEVA SWOT Analysis: Financial Struggles Amidst Strategic Shifts Revealed in 10-Q Filing

TEVA Looks 71.0% Overvalued on GF Value™ as Insider Selling Persists

2026-07-30T00:00:09.000Z - 4 weeks ago

TEVA Looks 71.0% Overvalued on GF Value™ as Insider Selling Persists

Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued

2026-07-29T23:44:57.000Z - 4 weeks ago

Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued

Stocks to Watch Recap: Ford, Caterpillar, Teva, Starbucks

2026-07-29T22:42:58.000Z - 4 weeks ago

Stocks to Watch Recap: Ford, Caterpillar, Teva, Starbucks

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations

2026-07-29T19:10:00.000Z - 4 weeks ago

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations

Teva CEO on Q2 earnings: 'Good growth across the whole portfolio'

2026-07-29T17:29:52.000Z - 4 weeks ago

Teva CEO on Q2 earnings: 'Good growth across the whole portfolio'

Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

2026-07-29T17:20:56.000Z - 4 weeks ago

Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views

Watch CNBC's full interview with Teva Pharmaceuticals CEO Richard Francis

2026-07-29T16:26:57.000Z - 4 weeks ago

Watch CNBC's full interview with Teva Pharmaceuticals CEO Richard Francis

Teva Pharmaceutical Industries Q2 2026 Disappoints: EPS 93.8% Below Estimates

2026-07-29T15:04:54.000Z - 4 weeks ago

Teva Pharmaceutical Industries Q2 2026 Disappoints: EPS 93.8% Below Estimates

TEVA Looks 56.0% Overvalued on GF Value™ as Insider Selling Persists

2026-07-29T13:08:24.000Z - 4 weeks ago

TEVA Looks 56.0% Overvalued on GF Value™ as Insider Selling Persists

Is Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges After Q2 Earnings Miss? GAAP ...

2026-07-29T12:32:50.000Z - 4 weeks ago

Is Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges After Q2 Earnings Miss? GAAP ...

Teva Pharmaceutical Industries Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 4 weeks ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q2 2026

Teva Pharmaceutical Industries Slides: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 4 weeks ago

Teva Pharmaceutical Industries Slides: Q2 2026

Teva Pharmaceutical Industries Earnings release: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 4 weeks ago

Teva Pharmaceutical Industries Earnings release: Q2 2026

Teva Pharmaceutical Industries Quarterly report: Q2 2026

Jul 29, 2026, 8:00 AM EDT - 4 weeks ago

Teva Pharmaceutical Industries Quarterly report: Q2 2026

Teva Pharmaceutical Industries Releases Q2 2026 Financial Results

2026-07-29T11:59:51.000Z - 4 weeks ago

Teva Pharmaceutical Industries Releases Q2 2026 Financial Results

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Wed, 29 Jul 2026 07:42:00 -0400 - 4 weeks ago

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Wed, 29 Jul 2026 07:24:00 -0400 - 4 weeks ago

Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Teva reports Q2 EPS 2c, consensus 11c

2026-07-29T11:22:16.000Z - 4 weeks ago

Teva reports Q2 EPS 2c, consensus 11c

Teva Pharmaceutical Industries Q2 26 Earnings Conference Call At 8:00 AM ET

2026-07-29T11:00:29.000Z - 4 weeks ago

Teva Pharmaceutical Industries Q2 26 Earnings Conference Call At 8:00 AM ET

‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness

2026-07-29T07:30:00.000Z - 4 weeks ago

‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness

TEVA Looks 55.9% Overvalued on GF Value™ as Earnings Outlook Dims

2026-07-28T19:00:45.000Z - 4 weeks ago

TEVA Looks 55.9% Overvalued on GF Value™ as Earnings Outlook Dims

TEVA Maintained by Piper Sandler -- Price Target Raised to $44.00

2026-07-28T16:34:38.000Z - 4 weeks ago

TEVA Maintained by Piper Sandler -- Price Target Raised to $44.00

Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics

2026-07-28T13:15:04.000Z - 4 weeks ago

Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics

Teva price target raised to $44 from $42 at Piper Sandler

2026-07-28T10:51:24.000Z - 4 weeks ago

Teva price target raised to $44 from $42 at Piper Sandler

Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.

Sun, 26 Jul 2026 14:45:00 -0400 - 4 weeks ago

Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.

Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.

Sun, 26 Jul 2026 09:45:00 -0400 - 4 weeks ago

Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.

Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat

2026-07-23T17:27:00.000Z - 5 weeks ago

Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

Wed, 22 Jul 2026 09:16:35 -0400 - 5 weeks ago

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

Noteworthy ETF Outflows: EFA, SPOT, NBIS, TEVA

2026-07-21T14:51:09.000Z - 5 weeks ago

Noteworthy ETF Outflows: EFA, SPOT, NBIS, TEVA

A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.2% Decline -- GF Value $20. ...

2026-07-20T22:25:30.000Z - 5 weeks ago

A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.2% Decline -- GF Value $20. ...

Teva (TEVA) Sees 2% Rise After Seven-Day Decline

2026-07-16T17:59:19.000Z - 6 weeks ago

Teva (TEVA) Sees 2% Rise After Seven-Day Decline

Colin Cieszynski's Past Picks: First Quantum Minerals, Teva Pharmaceuticals & BMO Global Gold Index

2026-07-15T17:35:00.000Z - 6 weeks ago

Colin Cieszynski's Past Picks: First Quantum Minerals, Teva Pharmaceuticals & BMO Global Gold Index

Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Sun, 12 Jul 2026 18:02:15 -0400 - 6 weeks ago

Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Thu, 09 Jul 2026 12:12:04 -0400 - 7 weeks ago

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar

2026-07-09T12:56:21.000Z - 7 weeks ago

Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Thu, 09 Jul 2026 08:45:00 -0400 - 7 weeks ago

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva, Polpharma Biologics announce global licensing agreement

2026-07-09T12:40:32.000Z - 7 weeks ago

Teva, Polpharma Biologics announce global licensing agreement

Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ

2026-07-09T12:17:10.000Z - 7 weeks ago

Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ

Teva Pharmaceutical Industries Transcript: Study result

Jul 7, 2026, 8:00 AM EDT - 7 weeks ago

Teva Pharmaceutical Industries Transcript: Study result

Teva Pharmaceutical Industries Press release: Study result

Jul 7, 2026, 8:00 AM EDT - 7 weeks ago

Teva Pharmaceutical Industries Press release: Study result

Teva Pharmaceutical Industries Slides: Study result

Jul 7, 2026, 8:00 AM EDT - 7 weeks ago

Teva Pharmaceutical Industries Slides: Study result

Teva to advance TEV-‘408 into Phase 2b study in vitiligo in Q4

2026-07-07T11:05:09.000Z - 7 weeks ago

Teva to advance TEV-‘408 into Phase 2b study in vitiligo in Q4

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Jun 18, 2026, 4:57 PM EDT - 2 months ago

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Jun 18, 2026, 4:30 PM EDT - 2 months ago

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Jun 11, 2026, 3:03 PM EDT - 2 months ago

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Jun 10, 2026, 12:03 PM EDT - 2 months ago

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva Pharmaceutical Industries Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Teva Pharmaceutical Industries Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Jun 5, 2026, 11:30 AM EDT - 3 months ago

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva to Present at the Goldman Sachs Global Healthcare Conference

Jun 1, 2026, 4:30 PM EDT - 3 months ago

Teva to Present at the Goldman Sachs Global Healthcare Conference

The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

May 21, 2026, 12:30 PM EDT - 3 months ago

The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

May 18, 2026, 8:30 AM EDT - 3 months ago

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

May 18, 2026, 8:00 AM EDT - 3 months ago

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

TD

Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 12:20 PM EDT - 3 months ago

Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2026

Teva to Present at the BofA Securities Health Care Conference

May 4, 2026, 4:30 PM EDT - 4 months ago

Teva to Present at the BofA Securities Health Care Conference

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Apr 30, 2026, 8:30 AM EDT - 4 months ago

Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Apr 29, 2026, 2:22 PM EDT - 4 months ago

Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio

Teva Pharmaceutical Industries Transcript: M&A announcement

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Teva Pharmaceutical Industries Transcript: M&A announcement

Teva Pharmaceutical Industries Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q1 2026

Teva Pharmaceutical Industries Slides: M&A announcement

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Teva Pharmaceutical Industries Slides: M&A announcement

Teva Pharmaceutical Industries Press release: M&A announcement

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Teva Pharmaceutical Industries Press release: M&A announcement

Teva Pharmaceutical Industries Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Teva Pharmaceutical Industries Slides: Q1 2026

Teva Pharmaceutical Industries Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Teva Pharmaceutical Industries Earnings release: Q1 2026

Teva Pharmaceutical Industries Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Teva Pharmaceutical Industries Quarterly report: Q1 2026

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Apr 29, 2026, 7:05 AM EDT - 4 months ago

Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Apr 29, 2026, 6:30 AM EDT - 4 months ago

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Teva Pharmaceutical Industries Proxy statement: Proxy filing

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva Releases Q1 2026 Aide Memoire

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Teva Releases Q1 2026 Aide Memoire

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Mar 19, 2026, 4:30 PM EDT - 5 months ago

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

Teva Pharmaceutical Industries Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Teva Pharmaceutical Industries Transcript: Barclays 28th Annual Global Healthcare Conference

Teva Pharmaceutical Industries Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:00 AM EDT - 6 months ago

Teva Pharmaceutical Industries Transcript: Leerink Global Healthcare Conference 2026

Teva to Present at the Upcoming Investor Conferences in March

Feb 24, 2026, 4:30 PM EST - 6 months ago

Teva to Present at the Upcoming Investor Conferences in March

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Feb 20, 2026, 2:43 PM EST - 6 months ago

U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva Pharmaceutical Industries Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 6 months ago

Teva Pharmaceutical Industries Transcript: Study result

Teva Pharmaceutical Industries Press release: Study result

Feb 17, 2026, 8:00 AM EST - 6 months ago

Teva Pharmaceutical Industries Press release: Study result

Teva Pharmaceutical Industries Slides: Study result

Feb 17, 2026, 8:00 AM EST - 6 months ago

Teva Pharmaceutical Industries Slides: Study result

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Feb 17, 2026, 6:00 AM EST - 6 months ago

Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Teva Pharmaceutical Industries Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 13, 2026, 9:30 AM EST - 7 months ago

Teva Pharmaceutical Industries Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Teva Pharmaceutical Industries Earnings Call Transcript: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Earnings Call Transcript: Q4 2025

Teva Pharmaceutical Industries Annual report: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Annual report: Q4 2025

Teva Pharmaceutical Industries Earnings release: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Earnings release: Q4 2025

Teva Pharmaceutical Industries Slides: Q4 2025

Jan 28, 2026, 8:00 AM EST - 7 months ago

Teva Pharmaceutical Industries Slides: Q4 2025

Teva Pharmaceutical profit, revenue rise in fourth quarter

Jan 28, 2026, 7:31 AM EST - 7 months ago

Teva Pharmaceutical profit, revenue rise in fourth quarter

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Jan 28, 2026, 7:00 AM EST - 7 months ago

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

Jan 27, 2026, 8:00 AM EST - 7 months ago

Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Jan 14, 2026, 5:02 PM EST - 8 months ago

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Teva Pharmaceutical Industries Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 8 months ago

Teva Pharmaceutical Industries Transcript: 44th Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 11:15 AM EST - 8 months ago

Teva Pharmaceutical Industries Slides: 44th Annual J.P. Morgan Healthcare Conference

Why Investors Are So Optimistic on Teva

Jan 12, 2026, 10:46 AM EST - 8 months ago

Why Investors Are So Optimistic on Teva

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Jan 11, 2026, 6:00 PM EST - 8 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:00 PM EST - 8 months ago

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:30 PM EST - 8 months ago

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Dec 24, 2025, 8:36 AM EST - 8 months ago

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Dec 19, 2025, 3:40 AM EST - 9 months ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Dec 9, 2025, 8:00 AM EST - 9 months ago

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva Pharmaceutical Industries Transcript: Citi Annual Global Healthcare Conference 2025

Dec 4, 2025, 10:30 AM EST - 9 months ago

Teva Pharmaceutical Industries Transcript: Citi Annual Global Healthcare Conference 2025

Teva Pharmaceutical Industries Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 11:00 AM EST - 9 months ago

Teva Pharmaceutical Industries Transcript: Piper Sandler 37th Annual Healthcare Conference

Teva Pharmaceutical Industries Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 8:20 AM EST - 9 months ago

Teva Pharmaceutical Industries Transcript: Evercore ISI 8th Annual HealthCONx Conference

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Nov 25, 2025, 8:10 AM EST - 9 months ago

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Nov 21, 2025, 4:30 PM EST - 10 months ago

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

Teva seeks startups to help solve global pharmaceutical challenges

Nov 19, 2025, 8:07 AM EST - 10 months ago

Teva seeks startups to help solve global pharmaceutical challenges

Teva Pharmaceutical Industries Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 6:00 AM EST - 10 months ago

Teva Pharmaceutical Industries Transcript: Jefferies London Healthcare Conference 2025

Teva Pharmaceutical Industries Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 8:45 AM EST - 10 months ago

Teva Pharmaceutical Industries Transcript: UBS Global Healthcare Conference 2025

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Nov 7, 2025, 6:00 PM EST - 10 months ago

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Nov 5, 2025, 1:02 PM EST - 10 months ago

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Nov 5, 2025, 9:14 AM EST - 10 months ago

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Joebeemer
Joebeemer Aug. 29 at 2:32 AM
$TEVA when you look at this stick price over a long period of time. Especially like the 5yr timeline, it's been steadily rising. Dips occur,but it comes back higher. May have to hold longer but this should keep climbing
0 · Reply
Terrordomo80
Terrordomo80 Aug. 28 at 9:24 PM
$TEVA but...but...52 week highs...
0 · Reply
SdotRayborn
SdotRayborn Aug. 28 at 5:42 PM
$TEVA no volume until the 18th when it’s directly listed on the NYSE I guess. Volume been so dead for months.
0 · Reply
Paulbpaulb
Paulbpaulb Aug. 28 at 4:24 PM
$BTAI maybe it’s a good time to buy a chunk of $TEVA ?
1 · Reply
Joebeemer
Joebeemer Aug. 28 at 3:54 PM
$TEVA this should come up substantially with the acquisition news of $BTAI Maybe Mondays runners
0 · Reply
flychicken1991
flychicken1991 Aug. 28 at 10:31 AM
$TEVA Mixed (76%): shares could rise if the acquired product adds credible revenue and earnings potential at a disciplined cost, but they could be pressured if the purchase price, financing burden, regulatory risk... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/323214d3cd0bed30/teva-teva-announces-proposed-acquisition-of-a-novel-neuroscience-product?utm_source=stocktwits&utm_medium=story_url
0 · Reply
G101SPM
G101SPM Aug. 28 at 10:21 AM
$TEVA $37.21 bid Holding long position at $5.77 Review entire column https://stocktwits.com/G101SPM/message/646531082 UPDATE:Teva Pharma to serve as stalking horse bidder for substantially all BioXcel Therapeutics (BTAI) assets note: Teva Pharmaceutical Industries subsidiary Teva Pharmaceuticals International entered into an asset sale agreement to acquire substantially all of BioXcel Therapeutics' assets, subject to a court-supervised Chapter 11 auction process. Teva will serve as the sole stalking horse bidder, establishing the baseline offer for a Section 363 auction that allows competing bids for some or all of BioXcel's assets. Assets covered by the agreement include IGALMI (dexmedetomidine) sublingual film and the pending sNDA for BXCL501 for potential at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel concurrently filed for Chapter 11 protection and secured a $19 mln DIP financing commitment; the BXCL501 sNDA has a November 14, 2026 PDUFA date.
0 · Reply
Hopewisper
Hopewisper Aug. 28 at 5:22 AM
$TEVA
0 · Reply
layahoo
layahoo Aug. 28 at 3:05 AM
$TEVA Where’s that low lying weakling??? lol
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Aug. 27 at 7:01 PM
$TEVA printed a new 52-week high today
0 · Reply
DocDriz
DocDriz Aug. 27 at 6:06 PM
$TEVA Do your thing, little TEVA 🇮🇱
0 · Reply
NNJATRDR
NNJATRDR Aug. 26 at 11:51 PM
$TEVA new all time highs on the way
0 · Reply
Hopewisper
Hopewisper Aug. 26 at 9:39 AM
$TEVA Can you smell it....
0 · Reply
CapitalMonk
CapitalMonk Aug. 26 at 2:29 AM
$TEVA Price: $38.10 (+3.17%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.89% RSI: 75.7 | Momentum: Strong Momentum Volume: -12.2% vs avg Volatility: 2.46% Support: $33.48 | Resistance: $38.11 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
layahoo
layahoo Aug. 26 at 12:31 AM
$TEVA I’m out getting sloshed:)))
0 · Reply
SdotRayborn
SdotRayborn Aug. 25 at 7:52 PM
$TEVA December 31st, 1991, gap fill coming 😂
0 · Reply
SdotRayborn
SdotRayborn Aug. 25 at 6:33 PM
$TEVA 👍🏻
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Aug. 25 at 4:01 PM
$TEVA printed a new 52-week high today
0 · Reply
Jdorkshire
Jdorkshire Aug. 25 at 3:18 PM
$TEVA 52 Wk Hi here
0 · Reply
Albino_Trader123
Albino_Trader123 Aug. 25 at 3:16 PM
$TEVA Still holding above the massive base. Looking good
0 · Reply
11thestate
11thestate Aug. 25 at 1:16 PM
$TEVA Settlement Update: Teva has reached a tentative settlement with investors Investors claim that Teva concealed an illegal kickback scheme tied to Copaxone sales. In 2020, the DOJ alleged $328.6M in kickback payments, and $TEVA fell about 15% after the disclosure. If you purchased $TEVA between 2015 and 2020, you may be eligible to submit a claim: https://11th.com/cases/tevapharmaceuticalindustries-investor-settlement
0 · Reply
layahoo
layahoo Aug. 24 at 8:24 PM
$TEVA Love_To_Learn where are you??
0 · Reply